GSK2330811

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

Crohn's DiseaseCrohns DiseaseHealthy VolunteersScleroderma, Systemic

Phase 1

A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects

CompletedNCT02386436

GlaxoSmithKlineScleroderma, Systemic

Start: 2015-04-21End: 2016-04-11Updated: 2017-05-15

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants

CompletedNCT04138043

GlaxoSmithKlineHealthy Volunteers

Start: 2019-12-05End: 2020-05-28Updated: 2021-05-24

Phase 2

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

CompletedNCT03041025

GlaxoSmithKlineScleroderma, Systemic

Start: 2017-06-05End: 2020-07-07Updated: 2021-05-24

Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease

WithdrawnNCT04151225

GlaxoSmithKlineCrohn's Disease, Crohns Disease

Start: 2021-04-05End: 2025-05-26Updated: 2022-01-14

Related Papers

Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis

Lara D. Veeken2022-05-1829 citations

In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody.

2018-07-1238 citations